X4 Pharmaceuticals XFOR - オプションチェーン

X4 Pharmaceuticals Inc ([symbol]) オプションチェーン

オプションコール

行使価格	買値	売値	前回の価格	中間価格	建玉	最終取引
2.50	1.15	4.30	0.00	2.725	0	-
5.00	0.00	3.00	0.05	0.05	5	-
7.50	0.00	0.05	0.00	0.00	0	-

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

オプションプット

行使価格	買値	売値	中間価格	最終取引
2.50	0.00	3.00	0.00	-
5.00	0.65	4.20	2.425	-
7.50	1.00	6.00	3.50	-

銘柄コード	株価	出来高
SCAGScage Future	US$ 0.8489 (196.61%)	92.75M
SPHLSpringview Holdings Ltd	US$ 5.38 (125.20%)	40.61M
NOTVInotiv Inc	US$ 0.1638 (89.15%)	1.07B
RMSGReal Messenger Corporation	US$ 1.809 (64.45%)	199.97M
STISolidion Technology Inc	US$ 35.50 (56.32%)	38.55M
NUWENewellis Inc	US$ 0.1625 (-62.30%)	50M
NYXHNyxoah SA	US$ 1.41 (-51.04%)	2.47M
CYPHCypherpunk Technologies Inc	US$ 0.5176 (-47.26%)	30.53M
TDICDreamland Ltd	US$ 0.2277 (-37.68%)	12.09M
FOFOHang Feng Technology Innovation Co Ltd	US$ 3.91 (-36.73%)	381.9k
NOTVInotiv Inc	US$ 0.1638 (89.15%)	1.07B
SNBRSleep Number Corporation	US$ 0.477 (36.25%)	305.13M
SMTKSmartKem Inc	US$ 0.419101 (30.97%)	232.19M
NVDANVIDIA Corporation	US$ 205.10 (-6.20%)	220.65M
RMSGReal Messenger Corporation	US$ 1.809 (64.45%)	199.97M

銘柄コード

株価

出来高

NOTVInotiv Inc

US$ 0.1638

(89.15%)

1.07B

SNBRSleep Number Corporation

US$ 0.477

(36.25%)

305.13M

SMTKSmartKem Inc

US$ 0.419101

(30.97%)

232.19M

NVDANVIDIA Corporation

US$ 205.10

(-6.20%)

220.65M

RMSGReal Messenger Corporation

US$ 1.809

(64.45%)

199.97M

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 2, 2026

BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on March 31, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the "2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 32,000 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.

The options have a ten-year term and an exercise price of $4.13 per share, which is equal to the closing price of X4’s common stock on March 31, 2026. Each option will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employee’s continued employment with X4 on such vesting dates. The options are subject to the terms and conditions of the 2019 Inducement Plan and the terms and conditions of an award agreement covering the grant.

About X4 Pharmaceuticals
X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs. Leveraging expertise in diseases of the immune system and CXCR4 biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is commercially available in the U.S. as XOLREMDI® in its first indication. The Company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenic disorders. The U.S. FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.

Link article

$XFOR 🗞️